Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors.

Ryan B Corcoran Khanh T Do Jeong Eun Kim James M Cleary Aparna Raj Parikh Oladapo O Yeku Niya Xiong Colin D Weekes Jennifer T Veneris Leanne G Ahronian Gianluca Mauri Jun Tian Bryanna L Norden Alexa G Michel Emily E Van Seventer Giulia Siravegna Kyle Camphausen Gary Chi Isobel J Fetter Joan S Brugge Helen X Chen Naoko Takebe Richard T Penson Dejan Juric Keith T Flaherty Ryan J Sullivan Jeffrey W Clark Rebecca S Heist Ursula A Matulonis Joyce F Liu Geoffrey I Shapiro

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Navitoclax in combination with trametinib was tolerable. Durable clinical responses were observed in patients with RAS-mutant GYN cancers, warranting further evaluation in this population.

Keyphrases

wild type
open label
pi k akt
clinical trial
double blind
placebo controlled